September 2008- Volume 4, Issue 9
In this Issue
Genomics & Proteomics
Rosetta, NIH to ID microRNA drug targets
Rosetta, NIH to ID microRNA drug targets
In a collaboration that aims to find potential drug targets for treating human immunodeficiency virus (HIV) infection, Rosetta Genomics—which has headquarters both in Israel and Jersey City, N.J.—will work with the National Institutes of Health (NIH) to identify microRNAs implicated in HIV viral replication and their function.
Follow the leader
Follow the leader
Alnylam arranges licenses to gain dominant IP position in RNAa
‘Zoom lens’ for sequencing
‘Zoom lens’ for sequencing
TGen and febit collaborate to refine new DNA capture method
Focus on the gene scene
Focus on the gene scene
Broad Institute releases free Integrative Genomics Viewer
Of mice and HIV models
Of mice and HIV models
Researchers come up with a more humanized HIV mouse model
Research & Development
Making their mark
Making their mark
Biomarker company Clinical Data acquires Adenosine Therapeutics
What’s old is new again
What’s old is new again
PhytoMedical to develop Dartmouth’s forgotten cancer compounds
Clear kidney connection
Clear kidney connection
Cytochroma, Mitsubishi Tanabe ink deal for chronic kidney disease therapeutics
Venturing into vaccines
Venturing into vaccines
Sanofi Pasteur to buy vaccine supplier Acambis
Changing the R&D landscape
Changing the R&D landscape
Lilly sells Greenfield Labs, signs 10-year, $1.6 billion R&D deal with Covance
Feature
Take a really good look
Take a really good look
Mining data may be the easy part; visualizing it for proper analysis and development is the big challenge now
Automation & Instrumentation
Caliper extends screening services
Caliper extends screening services
Adds RapidKinase profiling and enzymatic mechanism of action studies
Fluorescent tags for live cells
Fluorescent tags for live cells
Promega, Leica set sights on sub 100 nm live cell imaging
Custom-made deal
Custom-made deal
Invitrogen, Lentigen to provide custom lentiviral gene-overexpression products
Multi-mode partnership
Multi-mode partnership
BioTek and fledgling assay company Gyrasol sign co-marketing agreement
Informatics
A broader protein vision
A broader protein vision
Waters teams with Proteome Software for protein visualization
Clinic-to-research connection
Clinic-to-research connection
Sealy Center, GenoLogics to develop biomedical informatics solution
A sum greater than its parts
A sum greater than its parts
SDI combines forces with Verispan to create comprehensive healthcare industry database
Breaking down clinical barriers
Breaking down clinical barriers
Pharsight, CRI Worldwide team up to improve clinical trial efficiency
The power of Pattern Array
The power of Pattern Array
University of Maryland researchers see commercial opportunity for novel data mining software
Commentary
Pharma faces Congressional battles in 2009
Pharma faces Congressional battles in 2009
Industry sees little difference in proposed policies of Obama and McCain
At what cost (overzealous) reactions?
At what cost (overzealous) reactions?
Franklin Roosevelt suggested that “the only thing we have to fear is fear itself.” There are many other things to fear, and one of them is poorly reported medical data.
Editor's Focus
Few bargains in biotech acquisitions
Few bargains in biotech acquisitions
A funny thing happened on the way to the biotech bargain basement the big companies had been picking over, the pharmas and biotechs on display like so many shirts on a clearance rack at Nordstrom’s: the acquisition targets started saying, “No, we don’t want your funny billion dollars, we’re worth more.”
Global News
MediGene sells European Oracea rights to Galderma
MediGene sells European Oracea rights to Galderma
Milestone payments to total up to E32 million
Valeant, Meda strike multiple deals
Valeant, Meda strike multiple deals
Valeant sells Western, Eastern Europe operations to Meda for $392 million
Back in the game
Back in the game
PDL BioPharma inks deal with Bristol-Myers Squibb for multiple myeloma candidate elotuzumab
Alpharma: ‘No thanks’ to $1.4 billion offer
Alpharma: ‘No thanks’ to $1.4 billion offer
King Pharmaceuticals makes unsolicited $33 per share bid for specialty pharma company
ImClone says no to BMS
ImClone says no to BMS
Oncology biopharma rejects BMS' $4.5B acquisition offer
